Rizatriptan EP Impurity I: Chemical Structure, Characterization, and Analytical Significance
Pharmaceutical impurity profiling is an essential part of drug development, analytical research, and quality control. Identifying and monitoring impurities in active pharmaceutical ingredients (APIs) helps manufacturers evaluate product quality, maintain consistency, and meet applicable pharmaceutical quality requirements. Impurity characterization is particularly important when developing analytical methods and assessing the purity of pharmaceutical substances.
Rizatriptan EP Impurity I, also known as N-Desmethyl Rizatriptan, is a related compound associated with the analysis of Rizatriptan. Rizatriptan is a selective serotonin 5-HT1B/1D receptor agonist used in the treatment of migraine attacks. During pharmaceutical development and manufacturing, related substances may require investigation to understand their chemical identity and monitor their presence in the drug substance.
Studying Rizatriptan EP Impurity I provides analytical researchers with useful information for impurity identification, chromatographic separation, and pharmaceutical quality assessment. Appropriate reference materials can also support analytical method development and help laboratories evaluate related substances in Rizatriptan samples.
1. Chemical Structure and Molecular Characteristics
Rizatriptan EP Impurity I is identified as N-Desmethyl Rizatriptan. Its molecular structure contains an indole ring system, a triazole-containing substituent, and an ethylamine side chain.
The compound differs from Rizatriptan through the removal of a methyl substituent from the terminal amino group. This structural difference is important when evaluating related substances because even a relatively small molecular modification can influence chromatographic retention, mass spectrometric response, and other analytical characteristics.
Key chemical information:
Parameter | Details |
Product name | |
Synonym | N-Desmethyl Rizatriptan |
CAS Number | 144034-84-4 |
CAT Number | CP-R18009 |
Molecular formula | C14H17N5 |
Molecular weight | 255.33 g/mol |
Parent API | Rizatriptan |
Understanding these molecular characteristics provides a starting point for selecting appropriate analytical techniques and investigating the compound in pharmaceutical samples.
2. Formation and Pharmaceutical Relevance
The presence of related substances in pharmaceutical materials can be associated with different stages of drug substance development and manufacturing. Potential sources include starting materials, intermediate compounds, chemical transformations, process-related variations, and degradation pathways.
For N-Desmethyl Rizatriptan, the structural relationship with Rizatriptan makes it relevant to the investigation of changes involving the API's terminal amino group.
However, the actual formation pathway and presence of this impurity should be established through suitable experimental evidence rather than assumed solely from its chemical structure.
Understanding related compounds is important for pharmaceutical manufacturers because it supports:
Investigation of process-related impurities.
Assessment of related substances in API samples.
Development of suitable chromatographic separation methods.
Evaluation of analytical specificity.
Consistent monitoring of pharmaceutical material quality.
The identification of a related compound also helps analytical scientists distinguish the intended API from structurally similar substances during routine testing.
3. Analytical Characterization of Rizatriptan EP Impurity I
Analytical characterization is necessary to establish the identity and evaluate the chemical properties of pharmaceutical impurities. Different analytical techniques provide complementary information, allowing researchers to investigate molecular structure, chromatographic behaviour, and sample composition.
High-Performance Liquid Chromatography (HPLC)
HPLC is widely used in pharmaceutical laboratories for the separation and analysis of active pharmaceutical ingredients and related substances.
For Rizatriptan EP Impurity I, HPLC can be used to investigate chromatographic separation from Rizatriptan and other related compounds. Appropriate stationary phases, mobile-phase compositions, and analytical conditions should be evaluated during method development.
The selection of suitable conditions depends on the chemical properties of the analyte, sample matrix, and analytical objective.
Liquid Chromatography–Mass Spectrometry (LC-MS)
LC-MS combines chromatographic separation with mass-based detection. It can provide valuable information for investigating the molecular identity of related substances.
For N-Desmethyl Rizatriptan, mass spectrometric analysis can support the evaluation of its molecular characteristics and help distinguish it from the parent drug and other related compounds.
Theoretical molecular mass alone is not sufficient for definitive identification. Reliable characterization should consider appropriate reference materials, mass accuracy, fragmentation behaviour, and supporting analytical evidence.
Nuclear Magnetic Resonance (NMR) Spectroscopy
NMR spectroscopy provides detailed information about the chemical environment of hydrogen and carbon atoms within a molecule.
For Rizatriptan EP Impurity I, proton NMR and carbon NMR can support structural confirmation by examining the indole framework, triazole-containing region, and ethylamine side chain.
NMR is particularly useful when researchers need to investigate structural differences between an API and its related substances.
Complementary Analytical Techniques
Depending on the analytical requirements, additional techniques such as infrared spectroscopy (IR), UV spectroscopy, and suitable purity assessment methods may provide supporting information.
Using complementary analytical techniques helps laboratories develop a more complete understanding of an impurity's identity and characteristics.
4. Importance in Pharmaceutical Quality Control
Quality control laboratories play an important role in maintaining the consistency and quality of pharmaceutical ingredients. Monitoring related substances is a key part of this process, particularly when structurally related compounds may be present in an API sample.
Rizatriptan EP Impurity I can serve as an analytical reference material when investigating related substances in Rizatriptan samples.
Its importance in pharmaceutical quality control includes:
Impurity identification: Helps analytical researchers investigate and identify N-Desmethyl Rizatriptan in pharmaceutical samples.
Method development: Supports the development and optimization of chromatographic methods for separating related substances.
Analytical specificity: Provides a reference material for assessing whether an analytical method can distinguish the target impurity from the parent API and other related compounds.
Quality assessment: Supports the investigation of impurity profiles during pharmaceutical development and routine analytical studies.
Research and characterization: Helps researchers examine the structural and analytical characteristics of Rizatriptan-related compounds.
The use of suitable reference materials improves the reliability of analytical investigations. However, the suitability of a particular standard for a regulated test should always be established against the applicable pharmacopoeial requirements and the laboratory's intended analytical procedure.
5. Role of Reference Standards in Impurity Analysis
Pharmaceutical impurity reference standards are important tools for analytical laboratories because they provide characterized materials for comparison during testing.
For Rizatriptan EP Impurity I, an appropriate reference standard can support chromatographic identification, analytical method development, and impurity profiling.
When selecting an impurity reference standard, researchers should consider several factors:
Correct chemical identity and molecular structure.
Appropriate documentation, including a Certificate of Analysis (COA).
Available analytical characterization data.
Batch-specific purity information.
Suitable storage and handling recommendations.
Traceability and consistency of supplied documentation.
A Certificate of Analysis provides important information about the identity and analytical characteristics of a supplied batch. It should be reviewed before using the material in laboratory investigations.
6. Chemicea's Contribution to Pharmaceutical Impurity Reference Standards
Chemicea Pharmaceuticals Pvt. Ltd. is a chemistry-driven pharmaceutical company and contract research organization specializing in pharmaceutical impurity reference standards, custom synthesis, and analytical solutions.
The company supports pharmaceutical manufacturers, research organizations, and analytical laboratories by developing and supplying reference materials for different pharmaceutical applications.
Its areas of expertise include:
Pharmaceutical process impurities.
Degradation products.
Nitrosamine impurities.
Metabolites and glucuronides.
Stable-isotope-labelled compounds.
Custom synthesis of specialized pharmaceutical reference materials.
Analytical research and characterization support.
For laboratories investigating Rizatriptan-related substances, Chemicea offers Rizatriptan EP Impurity I (CP-R18009) as a reference material for research and analytical applications.
According to the available Chemicea Certificate of Analysis, the product is identified by CAS Number 144034-84-4, with molecular formula C14H17N5 and molecular weight 255.33 g/mol. The documented analytical characterization includes LC-MS, HPLC, and proton NMR. The referenced batch COA reports an HPLC result of 99.50%; this is a batch-specific result, not a universal specification for every batch.
Chemicea's focus on chemical development, impurity standards, and custom synthesis supports laboratories requiring specialized reference materials for pharmaceutical research and analytical investigations.
7. Storage and Handling Considerations
Proper storage and handling are important for maintaining the quality of pharmaceutical impurity reference materials.
According to Chemicea's available product documentation, Rizatriptan EP Impurity I should be stored tightly closed under an inert atmosphere at 2–8°C. The product is described as a light brown, slightly hygroscopic solid and is reported to be soluble in methanol and DMSO.
Laboratories should follow the storage instructions and handling recommendations provided in the current batch-specific documentation.
Appropriate laboratory precautions should also be followed during weighing, preparation, and analytical testing. Reference materials should be handled by trained personnel in accordance with relevant laboratory safety procedures.
Conclusion
Rizatriptan EP Impurity I, also known as N-Desmethyl Rizatriptan, is an important related compound for pharmaceutical analytical research involving Rizatriptan. Its molecular structure, chemical characteristics, and relationship with the parent API make it relevant to impurity identification, chromatographic separation, and pharmaceutical quality assessment.
Techniques such as HPLC, LC-MS, and NMR spectroscopy provide complementary information for investigating its identity and analytical properties. Appropriate reference standards further support method development, impurity profiling, and laboratory research.
Chemicea Pharmaceuticals contributes to this area through its range of pharmaceutical impurity reference standards, custom synthesis capabilities, and analytical research solutions. Its Rizatriptan EP Impurity I reference material provides an option for laboratories conducting research and analytical investigations involving Rizatriptan-related substances.
Frequently Asked Questions (FAQs)
1. What is Rizatriptan EP Impurity I?
Rizatriptan EP Impurity I, also known as N-Desmethyl Rizatriptan, is a structurally related compound of Rizatriptan. It is used as a reference material in pharmaceutical impurity identification and analytical research.
2. What is the CAS Number of Rizatriptan EP Impurity I?
The CAS Number of Rizatriptan EP Impurity I is 144034-84-4.
3. Which analytical techniques are used to characterize Rizatriptan EP Impurity I?
Commonly used techniques include HPLC, LC-MS, and NMR spectroscopy. These methods provide information about chromatographic behaviour, molecular characteristics, and structural identity.
4. Why are reference standards important for Rizatriptan impurity analysis?
Reference standards help analytical laboratories identify related compounds, develop chromatographic methods, evaluate analytical specificity, and investigate impurity profiles in pharmaceutical samples.
5. Where can I source Rizatriptan EP Impurity I?
Chemicea Pharmaceuticals offers Rizatriptan EP Impurity I (CAT No. CP-R18009) for research and analytical applications. Visit the product page for product details and documentation.
Comments